Abstract:Pancreatic ductal adenocarcinoma (PDAC) strongly resists standard therapies since KRAS-mutated cancer cells harbor endogenous resistance toward chemotherapy-induced apoptosis and tumor-associated macrophages (TAMs) activate stroma cells to create the nearly impenetrable matrix. Herein, we developed a tailored nanocomplex through the self-assembly of synthetic 4-(phosphonooxy)phenyl-2,4-dinitrobenzenesulfonate and Fe3+ followed by hyaluronic acid decoration, realizing chemodynamic therapy (CDT) to combat PDAC. By controllably releasing its components in a GSH-sensitive manner under the distinctive redox homeostasis in cancer cells and TAMs, the nanocomplex selectively triggered a Fenton reaction to induce oxidative damage in cancer cells and simultaneously repolarized TAMs to deactivate stromal cells and thus attenuate stroma. Compared to gemcitabine, CDT remarkably inhibited tumor growth and prolonged animal survival in orthotopic PDAC models without noticeable side effects. This study provides a promising strategy to improve the treatment of PDAC through CDT-mediated controlled cancer cells damage and reprogramming of the stromal microenvironment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c02622?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c02622</a>.Additional methods, materials, and experimental details; synthesis and characterization of PQS; preparation and characterization of HFePQS; distinctive redox homeostasis in cancer cells and non-neoplastic cells; cellular internalization of HFePQS in cancer cells; HFePQS damages cancer cells in vitro via oxidative stress-mediated cytotoxicity; the mechanistic roles of cancer cells and TAFs in activating TAFs; cellular internalization and cytotoxicity of HFePQS in non-neoplastic cells; direct regulation effect of HFePQS on TAFs in vitro; in vivo circulation profile and biodistribution of HFePQS; HFePQS controllably amplifies oxidative stress in cancer cells in vivo; HFePQS re-educates TAMs and reprograms the stromal microenvironment in vivo; HFePQS efficiently inhibits tumor growth and improves pancreatic cancer treatment (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c02622/suppl_file/nl0c02622_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

What problem does this paper attempt to address?

This paper attempts to solve several key problems in the treatment of pancreatic ductal adenocarcinoma (PDAC): 1. **Chemotherapy resistance**: Due to the intracellular endogenous resistance caused by KRAS mutations, the effect of standard chemotherapy on PDAC is not satisfactory. KRAS mutations are activated in 90% of PDAC patients, leading to an increase in intracellular reactive oxygen species (ROS) levels and thus resistance to chemotherapy drugs. 2. **Tumor microenvironment (TME) barriers**: Tumor - associated fibroblasts (TAFs), after being activated, produce a large amount of matrix proteins, which hinder drugs from entering the tumor microenvironment. In addition, tumor - associated macrophages (TAMs) release toxic factors in the M2 phenotype, further activating TAFs, increasing matrix deposition, and further hindering drug penetration. To overcome these problems, the research team has developed a self - assembling nanocomplex (HFePQS) to achieve the treatment of PDAC through chemodynamic therapy (CDT). Specifically: - **Selective oxidative stress induction**: HFePQS generates highly toxic hydroxyl radicals (•OH) in cancer cells through the Fenton reaction, inducing oxidative damage with less impact on normal cells. - **Remodeling the tumor microenvironment**: HFePQS can repolarize TAMs from the M2 phenotype to the M1 phenotype, reduce the activation of TAFs, decrease matrix deposition, and thus improve drug permeability. Through these mechanisms, HFePQS can not only effectively kill cancer cells but also remodel the tumor microenvironment and improve the treatment effect of PDAC. Compared with the traditional chemotherapy drug gemcitabine (Gem), HFePQS significantly inhibits tumor growth, prolongs the survival time of animals, and has no obvious side effects. In conclusion, this study provides a new treatment strategy to improve the treatment effect of PDAC by controllably damaging cancer cells and simultaneously remodeling the tumor microenvironment.

Tailored Chemodynamic Nanomedicine Improves Pancreatic Cancer Treatment via Controllable Damaging Neoplastic Cells and Reprogramming Tumor Microenvironment

PCN-Fe(III)-PTX Nanoparticles for MRI Guided High Efficiency Chemo-Photodynamic Therapy in Pancreatic Cancer Through Alleviating Tumor Hypoxia

Nanocatalytic Theranostics with Glutathione Depletion and Enhanced Reactive Oxygen Species Generation for Efficient Cancer Therapy

Self-assembled metal-polyphenolic based multifunctional nanomedicine to improve therapy treatment of pancreatic cancer by inhibition of glutamine metabolism

Manipulating Redox Homeostasis of Cancer Stem Cells Overcome Chemotherapeutic Resistance Through Photoactivatable Biomimetic Nanodiscs.

A Metal–Polyphenol‐Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy

Smart Hypoxia-Responsive Transformable and Charge-Reversible Nanoparticles for the Deep Penetration and Tumor Microenvironment Modulation of Pancreatic Cancer.

Photothermal nanozymes to self-augment combination cancer therapy by dual-glutathione depletion and hyperthermia/acidity-activated hydroxyl radical generation

Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy of Pancreatic Cancer

A Tumor‐Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer

Nanoscale coordination polymers enabling antioxidants inhibition for enhanced chemodynamic therapy

A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.

Endogenous Copper for Nanocatalytic Oxidative Damage and Self-Protection Pathway Breakage of Cancer

Tumor-specific activatable biopolymer nanoparticles stabilized by hydroxyethyl starch prodrug for self-amplified cooperative cancer therapy

Redox-activatable photothermal therapy and enzyme-mediated tumor starvation for synergistic cancer therapy

Prodrug-Based Nanoreactors with Tumor-Specific In Situ Activation for Multisynergistic Cancer Therapy

Cancer cell membrane-coated upconversion nanoparticles/Zn x Mn 1-x S core-shell nanoparticles for targeted photodynamic and chemodynamic therapy of pancreatic cancer

Nanoparticle-Mediated Inhibition of Mitochondrial Glutaminolysis to Amplify Oxidative Stress for Combination Cancer Therapy

Intelligent Nanoplatform with Multi Therapeutic Modalities for Synergistic Cancer Therapy

Oncocyte Membrane-Camouflaged Multi-Stimuli-Responsive Nanohybrids for Synergistic Amplification of Tumor Oxidative Stresses and Photothermal Enhanced Cancer Therapy

Tumor-targeted supramolecular catalytic nanoreactor for synergistic chemo/chemodynamic therapy via oxidative stress amplification and cascaded Fenton reaction